Case Study: Building Next-Generation LNPs with Gangliosides Instead of PEG to Reinvent Safety & Mitigate Immunogenicity
Time: 8:30 am
day: Conference Day Two
Details:
- Cytodigm successfully developed CytofinityTM LNP by replacing the PEG-lipid with a ganglioside in the LNP formulation
- The Cytofinity LNP can load various nucleic acid cargos and exhibited good colloidal stability, high encapsulation efficiency, and excellent safety profile
- The Cytofinity LNP possesses all the benefits of traditional LNPs while also offering additional advantages and capabilities
